Diagnostic magnetic resonance imaging of atherosclerosis in apolipoprotein e knockout mouse model using macrophage-targeted gadolinium-containing synthetic lipopeptide nanoparticles

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Shen, Zu T ^a   Zheng, Shaokuan ^b   Gounis, Matthew J ^b   Sigalov, Alexander B ^a  

^a SignaBlok Inc   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; GADOLINIUM; GADOLINIUM BASED CONTRAST AGENT USING HIGH DENSITY LIPOPROTEIN NANOPARTICLE; HIGH DENSITY LIPOPROTEIN; NANOPARTICLE; RHODAMINE B; UNCLASSIFIED DRUG; CONTRAST MEDIUM; LIPOPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ATHEROSCLEROSIS; CARDIAC IMAGING; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CYTOPLASM; DRUG DETERMINATION; DRUG SCREENING; DRUG SYNTHESIS; DRUG UPTAKE; HEPATIC CLEARANCE; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MACROPHAGE; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; SINGLE DRUG DOSE; ANIMAL; AORTA; ATHEROSCLEROTIC PLAQUE; CELL LINE; CHEMISTRY; CONFOCAL MICROSCOPY; DEFICIENCY; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; FLUORESCENCE; METABOLISM; PATHOLOGY;

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELL LINE; CONTRAST MEDIA; CYTOPLASM; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FLUORESCENCE; GADOLINIUM; LIPOPEPTIDES; LIPOPROTEINS, HDL; MACROPHAGES; MAGNETIC RESONANCE IMAGING; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL; NANOPARTICLES; PLAQUE, ATHEROSCLEROTIC;

EID: 84957110322     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143453     Document Type: Article

References (37)

1. Michaud CM, Murray CJ, Bloom BR (2001) Burden of disease-implications for future research. JAMA 285: 535-539. PMID: 11176854
2. Shah PK (2002) Pathophysiology of coronary thrombosis: role of plaque rupture and plaque erosion. Prog Cardiovasc Dis 44: 357-368. PMID: 12024334
3. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. (2003) From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 108: 1664-1672. PMID: 14530185
4. Bhatia V, Bhatia R, Dhindsa S, Virk A (2003) Vulnerable plaques, inflammation and newer imaging modalities. J Postgrad Med 49: 361-368. PMID: 14699240
5. Sharif F, Murphy RT (2010) Current status of vulnerable plaque detection. Catheter Cardiovasc Interv 75: 135-144. PMID: 19670307
6. Schaar JA, Mastik F, Regar E, den Uil CA, Gijsen FJ, Wentzel JJ, et al. (2007) Current diagnostic modalities for vulnerable plaque detection. Curr Pharm Des 13: 995-1001. PMID: 17430163
7. Choudhury RP, Lee JM, Greaves DR (2005) Mechanisms of disease: macrophage-derived foam cells emerging as therapeutic targets in atherosclerosis. Nat Clin Pract Cardiovasc Med 2: 309-315. PMID: 16265535
8. Lusis AJ (2000) Atherosclerosis. Nature 407: 233-241. PMID: 11001066
9. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685-1695. PMID: 15843671
10. Wakhloo AK, Lieber BB, Seong J, Sadasivan C, Gounis MJ, Miskolczi L, et al. (2004) Hemodynamics of carotid artery atherosclerotic occlusive disease. J Vasc Interv Radiol 15: S111-121. PMID: 15101520
11. MacNeill BD, Jang IK, Bouma BE, Iftimia N, Takano M, Yabushita H, et al. (2004) Focal and multi-focal plaque macrophage distributions in patients with acute and stable presentations of coronary artery disease. J Am Coll Cardiol 44: 972-979. PMID: 15337206
12. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT (1994) Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 90: 775-778. PMID: 8044947
13. Rudd JH, Hyafil F, Fayad ZA (2009) Inflammation imaging in atherosclerosis. Arterioscler Thromb Vasc Biol 29: 1009-1016. doi: 10.1161/ATVBAHA.108.165563 PMID: 19304673
14. Sanz J, Fayad ZA (2008) Imaging of atherosclerotic cardiovascular disease. Nature 451: 953-957. doi: 10.1038/nature06803 PMID: 18288186
15. Choudhury RP, Fisher EA (2009) Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation. Arterioscler Thromb Vasc Biol 29: 983-991. doi: 10.1161/ATVBAHA.108.165498 PMID: 19213945
16. Grobner T (2006) Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21: 1104-1108. PMID: 16431890
17. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, et al. (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17: 2359-2362. PMID: 16885403
18. Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris ST, et al. (2007) Gadoliniumenhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 245: 168-175. PMID: 17704357
19. Rothblat GH, Mahlberg FH, Johnson WJ, Phillips MC (1992) Apolipoproteins, membrane cholesterol domains, and the regulation of cholesterol efflux. J Lipid Res 33: 1091-1097. PMID: 1431592
20. Jonas A (1986) Reconstitution of high-density lipoproteins. Methods Enzymol 128: 553-582. PMID: 3724523
21. Chen W, Vucic E, Leupold E, Mulder WJ, Cormode DP, Briley-Saebo KC, et al. (2008) Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol Imaging 3: 233-242. PMID: 19072768
22. Wang XS, Gruenstein E (1997) Rapid elevation of neuronal cytoplasmic calcium by apolipoprotein E peptide. J Cell Physiol 173: 73-83. PMID: 9326451
23. Tolar M, Keller JN, Chan S, Mattson MP, Marques MA, Crutcher KA (1999) Truncated apolipoprotein E (ApoE) causes increased intracellular calcium and may mediate ApoE neurotoxicity. J Neurosci 19: 7100-7110. PMID: 10436064
24. Amirbekian V, Lipinski MJ, Briley-Saebo KC, Amirbekian S, Aguinaldo JG, Weinreb DB, et al. (2007) Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A 104: 961-966. PMID: 17215360
25. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ (2010) The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 9: 325-338. doi: 10.1038/nrd3003 PMID: 20305665
26. Sigalov AB (2014) Nature-inspired nanoformulations for contrast-enhanced in vivo MR imaging of macrophages. Contrast Media Mol Imaging 9: 372-382. PMID: 24729189
27. Anantharamaiah GM, Hughes TA, Iqbal M, Gawish A, Neame PJ, Medley MF, et al. (1988) Effect of oxidation on the properties of apolipoproteins A-I and A-II. J Lipid Res 29: 309-318. PMID: 3132519
28. von Eckardstein A, Walter M, Holz H, Benninghoven A, Assmann G (1991) Site-specific methionine sulfoxide formation is the structural basis of chromatographic heterogeneity of apolipoproteins A-I, C-II, and C-III. J Lipid Res 32: 1465-1476. PMID: 1753217
29. Sigalov AB, Stern LJ (1998) Enzymatic repair of oxidative damage to human apolipoprotein A-I. FEBS Lett 433: 196-200. PMID: 9744793
30. Pankhurst G, Wang XL, Wilcken DE, Baernthaler G, Panzenbock U, Raftery M, et al. (2003) Characterization of specifically oxidized apolipoproteins in mildly oxidized high density lipoprotein. J Lipid Res 44: 349-355. PMID: 12576517
31. Oda MN, Hargreaves PL, Beckstead JA, Redmond KA, van Antwerpen R, Ryan RO (2006) Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B. J Lipid Res 47: 260-267. PMID: 16314670
32. Sigalov AB, Stern LJ (2001) Oxidation of methionine residues affects the structure and stability of apolipoprotein A-I in reconstituted high density lipoprotein particles. Chem Phys Lipids 113: 133-146. PMID: 11687233
33. Sorci-Thomas MG, Curtiss L, Parks JS, Thomas MJ, Kearns MW, Landrum M (1998) The hydrophobic face orientation of apolipoprotein A-I amphipathic helix domain 143-164 regulates lecithin:cholesterol acyltransferase activation. J Biol Chem 273: 11776-11782. PMID: 9565601
34. Heier CR, Guerron AD, Korotcov A, Lin S, Gordish-Dressman H, Fricke S, et al. (2014) Non-invasive MRI and spectroscopy of mdx mice reveal temporal changes in dystrophic muscle imaging and in energy deficits. PLoS One 9: e112477. doi: 10.1371/journal.pone.0112477 PMID: 25390038
35. Barazza A, Blachford C, Even-Or O, Joaquin VA, Briley-Saebo KC, Chen W, et al. (2013) The complex fate in plasma of gadolinium incorporated into high-density lipoproteins used for magnetic imaging of atherosclerotic plaques. Bioconjug Chem 24: 1039-1048. doi: 10.1021/bc400105j PMID: 23617731
36. Korkusuz H, Ulbrich K, Bihrer V, Welzel K, Chernikov V, Knobloch T, et al. (2012) Contrast enhancement of the brain by folate-conjugated gadolinium-diethylenetriaminepentaacetic acid-human serum albumin nanoparticles by magnetic resonance imaging. Mol Imaging 11: 272-279. PMID: 22954143
37. Kuo PH, Abu-Alfa A, Bucala R, Griffith J, Carlson K, Girardi M, et al. (2009) MRI in the era of nephrogenic systemic fibrosis: Review, controversies and suggestons for risk reduction. Appl Radiol 38: 22-33.